New updates have been reported about Braveheart Bio.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Braveheart Bio’s lead asset, BHB-1893 (licensed as HRS-1893 from Hengrui Pharma outside Greater China), delivered positive Phase 2 results in non-obstructive hypertrophic cardiomyopathy (nHCM), a key validation of the company’s core thesis around next-generation cardiac myosin inhibition. In a multicenter, randomized, double-blind, placebo-controlled trial of 84 symptomatic nHCM patients, high-dose BHB-1893 rapidly and durably reduced NT-proBNP by about 68–69% and cardiac troponin I by 55–60% versus placebo, while driving structural reverse remodeling, including significant reductions in left ventricular mass index and wall thickness.
Clinically, patients on high-dose BHB-1893 showed placebo-adjusted improvement of 5.5 points in KCCQ-CSS, with 52% achieving at least a 20-point gain, and those titrated to 60 mg twice daily saw a 2.1 mL/kg/min increase in peak VO2, translating into a 0.9 mL/kg/min placebo-adjusted benefit. The drug was generally well tolerated, with no severe treatment-related adverse events, only four transient LVEF dips (all resolved after dose reduction), and no discontinuations due to safety, supporting Braveheart’s positioning of BHB-1893 as a potentially disease-modifying yet systolic-sparing CMI. Presented as late-breaking clinical research at the European Society of Cardiology’s Heart Failure 2026 congress, these results underpin Braveheart’s plan to advance BHB-1893 into a global registrational program in nHCM and complement ongoing development in obstructive HCM, reinforcing the company’s strategic focus on building a differentiated, clinically validated HCM franchise.